Exelixis
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 1.3K
- Market Cap
- $7.3B
- Website
- http://www.exelixis.com
- Introduction
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 730
- Registration Number
- NCT00940225
- Locations
- 🇺🇸
Pinnacle Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸Cancer Centers of the Carolinas, ITOR, Greenville, South Carolina, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 33
- Registration Number
- NCT00796484
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 330
- Registration Number
- NCT00704730
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Ohio State University, James Cancer Hospital, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Exelixis
- Registration Number
- NCT00704392
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York City, New York, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 222
- Registration Number
- NCT00704288
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 92
- Registration Number
- NCT00596648
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Georgetown University/Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Park Nicollet Institute, St. Louis Park, Minnesota, United States
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 3
- Registration Number
- NCT00595829
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸UCSF - Division of Hematology/Oncology, San Francisco, California, United States
🇺🇸UCLA School of Medicine, Center for Health Sciences, Los Angeles, California, United States
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
- Conditions
- Interventions
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 16
- Registration Number
- NCT00570635
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 84
- Registration Number
- NCT00526838
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
A Safety Study of XL019 in Adults With Myelofibrosis
- Conditions
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2011-04-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 100
- Registration Number
- NCT00522574
- Locations
- 🇺🇸
UCSF - Division of Hematology/Oncology, San Francisco, California, United States
🇺🇸Mt. Sinai School of Medicine, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States